美托洛尔联合曲美他嗪在冠心病心力衰竭患者中的疗效观察.docVIP

精品论文 参考文献 美托洛尔联合曲美他嗪在冠心病心力衰竭患者中的疗效观察 中铁二局集团中心医院 610000 【摘 要】目的：探讨美托洛尔联合曲美他嗪在冠心病心力衰竭患者中的疗效。方法：选取2014年5月-2016年7月在医院接受治疗的150例冠心病心力衰竭患者作为研究对象，随机分为观察组与对照组，每组患者75例，对照组患者采用常规治疗，观察组患者在对照组的基础上采用美托洛尔联合曲美他嗪治疗，分析两组患者治疗前后收缩压（SBP）、舒张压（DBP）、心率（HR）、左心室射血分数（LVEF）、左心室收缩末期内径（LVESD）和左心室舒张末期内径（LVEDD）等临床指标和临床疗效情况。结果：治疗前，两组患者SBP、DBP、HR、LVEF、LVESD和LVEDD等临床指标差异不明显，无统计学意义（P＞0.05）；治疗后，观察组患者SBP、DBP、HR、LVEF、LVESD和LVEDD等临床指标明显好于对照组，两组之间差异显著，具有统计学意义（P＜0.05）；观察组总有效率为92.0%，对照组为80.0%，观察组明显高于对照组，两组之间差异显著，具有统计学意义（P＜0.05）。结论：美托洛尔联合曲美他嗪在冠心病心力衰竭患者中的疗效显著，改善了生活质量和临床症状，临床上值得应用推广。 【关键词】美托洛尔；曲美他嗪；冠心病； Abstract Objective：To study the effect of metoprolol combined with trimetazidine on patients with coronary heart disease and heart failure. Methods：150 patients with coronary heart disease and heart failure who received treatment in our hospital during May 2012 to July 2016 were selected as study objects. They were randomly divided into observation group and control group，each containing 75 cases. Both groups went on routine treatment while patients in the observation group received additional treatment of metoprolol combined with trimetazidine. The clinical indicators and efficacy of treatment were investigated in both groups pre- and post-treatment. Results：No significant differences in clinical indicators were observed between two groups prior treatment（Pgt;0.05）. After treatment，observation group had superior clinical indicators over control group，which had a statistical significance（Plt;0.05）. The total effective rate of observation group，92.0%，was significantly higher than that of control group which was 80.0%（Plt;0.05）. Conclusion：Metoprolol combined with trimetazidine showed notable curative effect in patients with coronary heart disease and heart failure. Life quality and clinical symptoms were also improved. Therefore，metoprolol combined with trimetazidine could be extensively applied in the clinical practice. Key words：metoprolol；trimetazidine；coronary heart disease 冠心病（CHD）是一种常见的心脏疾病，